In a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Looking for patients with advanced colorectal cancer to test a new drug
In a nutshell This phase 1 study will investigate the dose range and effectiveness of an experimental drug, XmAb23104, in the treatment of advanced colorectal cancer and other solid tumors. The main outcome will be the safety and tolerability of XmAb23104. This trial is recruiting in Georgia, Texas, and Virginia, the United States. The details...
Read MoreEvaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma
In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...
Read MoreLooking for older patients with acute myeloid leukemia to test a new treatment combination
In a nutshell This study is evaluating how well CPI-613 plus chemotherapy works in older patients with acute myeloid leukemia (AML) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is taking place across the United...
Read MoreLooking for young patients with non-Hodgkin’s lymphoma to test a treatment combination
In a nutshell This phase 3 trial is comparing the effectiveness of ibrutinib (Imbruvica) plus chemotherapy versus chemotherapy alone in children and young adults with B-cell non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be survival without cancer returning, growing or spreading. The details Ibrutinib is a targeted therapy...
Read MoreEvaluating quality of life after pembrolizumab treatment for classical Hodgkin lymphoma
In a nutshell This phase 2 study evaluated the impact of pembrolizumab (Keytruda) on the quality of life of patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. This study concluded that the overall quality of life and health status was improved for these patients. Some background Most patients...
Read MoreOutcomes of stem cell transplant for patients with acute lymphoblastic leukemia after inotuzumab ozogamicin treatment
In a nutshell This study aimed to investigate the outcomes of allogeneic stem cell transplant (allo-SCT) after treatment with inotuzumab ozogamicin (Besponsa) for patients with relapsed/unresponsive acute lymphoblastic leukemia (ALL). This study concluded that allo-SCT provided optimal long-term survival benefit for these patients. Some...
Read MoreEvaluating PD-1 inhibitor therapy for recurrent or non-responsive classical Hodgkin lymphoma
In a nutshell This phase 2 study evaluated the effectiveness and safety of camrelizumab alone or in combination with decitabine (Dacogen) for recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that the combined treatment was safe and highly effective in these patients. Some background Standard first-line...
Read MoreEvaluating the FMT regimen before a stem cell transplant in patients with aggressive non-Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness of the FMT (fludarabine, melphalan, total body irradiation) regimen in patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that this regimen was well-tolerated and effective. Some background Many patients with aggressive NHL...
Read MoreSearching for participants to try a new combination of targeted therapy for relapsed or non-responsive B-cell lymphomas.
In a nutshell This study is investigating the effectiveness of a new combination of treatments, nivolumab (Opdivo) and varlilumab (CDX-1127), for non-responsive, aggressive B-cell lymphomas. The main outcome that will be measured is the proportion of patients that respond to treatment (overall response rate). This trial is recruiting in the US. The...
Read MoreEvaluating polatuzumab vedotin and pinatuzumab vedotin for relapsed or refractory NHL
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) combined with either polatuzumab vedotin (pola) or pinatuzumab vedotin (pina) for patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that pola was associated with better...
Read MoreSearching for patients with triple negative breast cancer to test this new treatment combination
In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...
Read More